A Phase I Multi-Center Study to Assess the Safety and Cardiovascular Effects of MyoCell™ Implantation in Patients With a Previous MI and Placement of an ICD Requiring De Novo Coronary Artery Bypass Graft Therapy
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Muscle-derived autologous stem cell therapy Bioheart (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Sponsors U.S. Stem Cell
- 27 Feb 2017 New trial record